Ethics and Science of Medicating Children

Topics: Psychiatry, Clinical trial, Placebo Pages: 25 (8471 words) Published: October 22, 2011
Ethical Human Psychology and Psychiatry, Volume 6, Number 1, Spring 2004

The Ethics and Science of Medicating Children
Jacqueline A. Sparks
The University of Rhode Island Kingston, RI

Barry L. Duncan
Institute for the Study of Therapeutic Change Ft. Lauderdale, FL Prescriptions for psychiatric drugs to children and adolescents have skyrocketed in the past 10 years. This article presents evidence that the superior effectiveness of stimulants and antidepressants is largely a presumption based on an empirical house of cards, driven by an industry that has no conscience about the implications of its ever growing, and disturbingly younger, list of consumers. Recognizing that most mental health professionals do not have the time, and sometimes feel ill-equipped to explore the controversy regarding pharmacological treatment of children, this article discusses the four fatal flaws of drug studies to enable a critical examination of research addressing the drugging of children. The four flaws are illustrated by the Emslie studies of Prozac and children, which offer not only a strident example of marketing masquerading as science, but also, given the recent FDA approval of Prozac for children, a brutal reminder of the danger inherent in not knowing how to distinguish science from science fiction. The authors argue that an ethical path requires the challenge of the automatic medical response to medicate children, with an accompanying demand for untainted science and balanced information to inform critical decisions by child caretakers.

D

uring the 1990s, prescriptions for psychiatric drugs to children and adolescents skyrocketed (Olfson, Marcus, Weissman, & Jensen, 2002; Zito et al., 2003). Evaluating the records of almost a million Medicaid and HMO youths, one of the largest and most comprehensive studies to date concluded that child and adolescent psychotropic utilization rates nearly tripled from pre-1990s levels (Zito et al., 2003). Total psychotropic prevalence for youths reached as high as 6.3%, rivaling adult rates. According to an IMS Health survey, between 1995 and 1999, the use of antidepressants increased 151% in the 7-12 age group and 580% in the under-6-years-old population. Children under 18-years-old saw a nearly 300% increase in the use of antipsychotic medications such as Risperdal (Diller, 2000). Drug Enforcement Administration records and national physician practice surveys indicate that approximately 4 million children took stimulants in 1998 (Diller). Even more alarming rates cluster in certain groups. Zito and colleagues found that children in foster care were 16 times more likely to receive a prescription than their non-foster care counterparts (2003). The Boston Globe reported that 1 in 8 teens in the state’s Medicaid © 2004 Springer Publishing Company 25

26

Sparks and Duncan

program was taking psychotropic medications, and 1 in 9 aged 6 to 12 years (8% and 13%, respectively; Barry, 2003). Between 1991 and 1995, pediatricians and psychiatrists wrote record numbers of stimulant, tricyclic antidepressant, clonidine hydrochloride, and SSRI prescriptions for preschoolers (Zito et al., 2000). Prescription rates for methylphenidate (Ritalin) for 2- through 4-year-olds grew by 169%. Zito and associates called such dramatic increases “remarkable in light of the limited knowledge base that underlies psychotropic medication use in very young children” (2000, p. 1026). In most major surveys of child and adolescent psychotropic use, stimulants are ranked as most popular, and antidepressants are ranked second. The research also points to an increasingly commonplace trend, polypharmacy, prescribing two or more medications simultaneously. According to one study, the rate of co-prescription rose significantly from 4.7% to 11.6% during 1987-1996 (Olfson, Marcus, Weissman, & Jensen, 2002). Children on stimulants for diagnoses of attention-deficit hyperactivity disorder (ADHD) are frequently prescribed...

References: Angell, M. (2000). Is academic medicine for sale? The New England Journal of Medicine, 342(20), 1516-1518. Asarnow, J. R., Jaycox, L. H., & Tompson, M. C. (2001). Depression in youth: Psychosocial interventions. Journal of Clinical Child Psychology, 30(1), 33-48. Barry, E. (2003, March 9). Guidelines pushed on child medication—Romney aide questions use of psychiatric drugs in Mass Health program. Boston Globe, p. 81. Birmaher, B., Ryan, N. D., Williamson, D. E., Brent, D. A., & Kaufman, J. (1996). Childhood and adolescent depression: A review of the past 10 years (Pt. II). Journal of the American Academy of Child Psychiatry, 35(12), 1575-1583. Bosely, S. (2003, June 10). Seroxat warning over risk to young. The Guardian. Retrieved July 23, 2003, from www.guardian.co.uk/uk_new/story/0,3604,974175/00.html Breggin, P. (1998). Talking back to Ritalin. Monroe, MA: Common Courage Press. Breggin, P. (2000a). Reclaiming our children: A healing plan for a nation in crisis. Cambridge, MA: Perseus Books. Breggin, P. (2000b). The NIMH multimodal study of treatment for attention-deficit/hyperactivity disorder: A critical analysis. International Journal of Risk & Safety in Medicine, 13, 15-22. Breggin, P., & Cohen, D. (1999). Your drug may be your problem: How and why to stop taking psychiatric medications. Cambridge, MA: Perseus. Brent, D. A., & Birmaher, B. (2002). Adolescent depression. The New England Journal of Medicine, 347, 667-671. Curry, J. F. (2001). Specific psychotherapies for childhood and adolescent depression. Biological Psychiatry, 49(12), 1091-1100.
38
Sparks and Duncan
Diller, L. H. (2000). Kids on drugs—A behavioral pediatrician questions the wisdom of medicating our children. Retrieved May 20, 2003, from http://www.salon.com/health/feature/2000/03/09/ kid_drugs/ Duncan, B., & Miller, S. (2000). The heroic client: Doing client directed, outcome informed therapy. San Francisco: Jossey Bass. Duncan, B., Miller, S., & Sparks, J. (2004). The heroic client: A revolutionary way to improve effectiveness through client-directed, outcome informed therapy. San Francisco: Jossey Bass. Duncan, B., Miller, S., Sparks, J., Jackson, G., Greenberg, R. P., & Kinchin, K. (in press). The myth of the magic pill. In B. Duncan, S. Miller, & J. Sparks, The heroic client: Becoming client directed and outcome informed (2nd ed.). San Francisco: Jossey Bass. Duncan, B., & Sparks, J. (2002). Heroic clients, heroic agencies: Partners for change. Fort Lauderdale, FL: ISTC Press. Emslie, G. J., Heiligenstein, J. H., Wagner, K. D., Hoog, S. L., Ernest, D. E., Brown, E., et al. (2002). Fluoxetine for acute treatment of depression in children and adolescents: A placebocontrolled, randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41(10), 1205-1215. Emslie, G. J., Rush, A. J., Weinberg, W. A., Kowatch, R. A., Hughes, C. W., Carmody, T., et al. (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54(11), 1031-1037. Evan, C., Siobud-Dorocant, E., & Dardennes, R. M. (2000). Critical approach to antidepressant trials: Blindness protection is necessary, feasible and measurable. The British Journal of Psychiatry, 177, 47-51. Fisher, R. L., & Fisher, S. (1997). Are we justified in treating children with psychotropic drugs? In S. Fisher & R. P. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test (pp. 307-322). New York: Wiley. Fisher, S., & Greenberg, R. P. (Eds.). (1997). From placebo to panacea: Putting psychiatric drugs to the test. New York: Wiley. Food and Drug Administration. (2003, January 3). FDA approves Prozac for pediatric use to treat depression and OCD. FDA Talk Paper. Retrieved February 2, 2003, from www.fda.gov/bbs/topics /ANSWERS/2003/ANSO1187.html Food and Drug Administration. (2003b, June 19). FDA statement regarding the anti-depressant Paxil for pediatric population. FDA Talk Paper. Available www.fda.gov/bbs/topics/ANSWERS/2003/ ANS01230.html Greenberg, R. P., Bornstein, R. F., Greenberg, M. D., & Fisher, S. (1992). A meta-analysis of antidepressant outcome under “blinder” conditions. Journal of Consulting and Clinical Psychology, 60, 664-669. Greenberg, R. P., & Fisher, S. (1997). Mood-mending medicines: Probing drug, psychotherapy, and placebo solutions. In S. Fisher & R.P. Greenberg (Eds.), From placebo to panacea: Putting psychiatric drugs to the test (pp. 115-172). New York: Wiley. Hughes, C. W., Emslie, G., Kowatch, R., Weinberg, W., Rintelmann, J., & Rush, A. J. (2000). Clinician, parent, and child prediction of medication or placebo in double-blind depression study. Neuropsychopharmacology, 23(5), 591-594. Keller, M. B., Ryan, N. D., Strober, M., Klein, R. G., Kutcher, S. P., Birmaher, B., et al. (2001). Efficacy of paroxetine in the treatment of adolescent major depression: A randomized, controlled trial. Journal of the American Academy of Child & Adolescent Psychiatry, 40(7), 762-772. Kong, D., & Bass, A. (1999, October 8). Case at Brown leads to review: NIMH studies tighter rules on conflicts. Boston Globe, p. B1. LeFever, G., Arcona, A., & Antonuccio, D. (in press). ADHD among American school children: Evidence of overdiagnosis and misuse of medication. Leo, J. (2002). American preschoolers on Ritalin. Society, 39, 52-60. Leo, J., & Cohen, D. (2003). Broken brains or flawed studies? A critical review of ADHD neuroimaging research. The Journal of Mind and Behavior, 24, 29-55.
Medicating Children
39
Lewinsohn, P. M., & Clarke, G. N. (1999). Psychosocial treatments for adolescent depression. Clinical Psychology Review, 19(3), 329-342. Michael, K. D., & Crowley, S. L. (2002). How effective are treatments for child and adolescent depression? A meta-analytic review. Clinical Psychology Review, 22(2), 247-269. Mitka, M. (2001). Mental health agenda now set for US children. Journal of American Mecical Association, 285(4), 398-399. MTA Cooperative Group. (1999). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56(12), 1073-1086. Mufson, L., Weissman, M. M., Moreau, D., & Garfinkel, R. (1999). Efficacy of interpersonal psychotherapy for depressed adolescents. Archives of General Psychiatry, 56(6), 573-579. National Institute of Mental Health. (2000). Treatment of children with mental disorders. Retrieved July 10, 2003, from http://www.nimh.nih.gov/publicat/childqa.cfm O’Connor, E. (2001, December). Medicating ADHD: Too much? Too soon? Monitor on Psychology, 32, 50-51. Olfson, M., Marcus, S. C., Weissman, M. M., & Jensen, P. S. (2002). National trends in the use of psychotropic medications by children. Journal of the American Academy of Child and Adolescent Psychiatry, 41(5), 514-521. Pelham, W. (1999). The NIMH multimodal treatment study for attention-deficit hyperactivity disorder: Just say yes to drugs alone. Canadian Journal of Psychiatry, 44, 981-990. Sasich, L. D., Lurie, P., & Wolfe, S. M. (2000). The drug industry’s performance in finishing postmarketing research (Phase IV) studies: A Public Citizen’s Health Research Group report. The Health Research Group. Retrieved June 6, 2003, from http://www.citizen.org/publications/ release.cfm?ID=6721 Vitiello, B. (1998). Pediatric psychopharmacology and the interaction between drugs and the developing brain. Canadian Journal of Psychiatry, 43(6), 582-584. Walkup, J. T. (2003, June 11). Pediatric psychopharmacology update. Family Therapy Magazine, 2(2), 34-36. Woolston, J. L. (1999). Combined pharmacotherapy: Pitfalls of treatment. Journal of Child & Adolescent Psychiatry, 38(11), 1455-1457. Zito, J. M., Safer, S. J., dosReis, S., Gardner, J. F., Boles, M., & Lynch, F. (2000). Trends in the prescribing of psychotropic medications to preschoolers. Journal of the American Medical Association, 283(8), 1025-1030. Zito, J. M., Safer, S. J., dosReis, S., Gardner, J. F., Magder, L., Soeken, K., et al. (2003). Psychotropic practice patterns for youth: A 10-year perspective. Archives of Pediatric & Adolescent Medicine, 157(1), 17-25. Zito, J., Safer, D., dosReis, S., & Riddle, M. (1998). Racial disparity in psychotropic medications prescribed for youths on Medicaid insurance in Maryland. Journal of the Academy of Child Adolescent Psychiatry, 37, 179-184. Acknowledgment. This article is adapted from The Heroic Client: Doing Client Directed, Outcome Informed Therapy by B. Duncan, S. Miller, and J. Sparks, in press, San Francisco: Jossey-Bass. Adapted with permission. Offprints. Requests for offprints should be directed to Jacqueline A. Sparks, PhD, 2750 NE 28th Court, Lighthouse Point, FL 33064. E-mail: jsparks@heroicagencies.org
Continue Reading

Please join StudyMode to read the full document

You May Also Find These Documents Helpful

  • Ethics Therapy for Children of Divorce Essay
  • Over Medicating Children Essay
  • Essay about The Dangers of Medicating Children for Behavioral Disorders
  • Essay on Ethics In Science
  • Ethics in Science Essay
  • Ethics and Science Essay
  • ethics of Essay
  • Ethics Essay

Become a StudyMode Member

Sign Up - It's Free